INT16388

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.79
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.46
Pain Relevance 1.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plg) extracellular space (Plg) extracellular region (Plg)
Anatomy Link Frequency
MVD 1
Plg (Mus musculus)
Pain Link Frequency Relevance Heat
Potency 6 100.00 Very High Very High Very High
Antinociceptive 7 99.48 Very High Very High Very High
Angina 8 94.96 High High
long-term potentiation 2 90.40 High High
narcan 1 85.84 High High
Opioid 2 83.56 Quite High
cva 21 66.88 Quite High
Inflammation 20 50.00 Quite Low
Hippocampus 3 44.76 Quite Low
Intracerebroventricular 2 41.96 Quite Low
Disease Link Frequency Relevance Heat
Disease 126 98.84 Very High Very High Very High
Coronary Artery Disease 2 97.16 Very High Very High Very High
Cv General 3 Under Development 21 94.96 High High
Brain Hemorrhage 1 92.96 High High
Myocardial Infarction 6 92.80 High High
Death 5 89.60 High High
Paralysis 1 85.92 High High
Cognitive Disorder 3 85.28 High High
Atherosclerosis 1 82.40 Quite High
Stroke 10 81.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, the t-PA-plasmin proteolytic cascade was found to promote the clearance of A?
Protein_catabolism (proteolytic) of plasmin
1) Confidence 0.79 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.59 Pain Relevance 0.05
Its antinociceptive activity, therefore, may be a consequence of both its PG synthetase inhibitory potency and another antinociceptive mechanism, the latter associated with its inhibitory potency in the MVD.
Protein_catabolism (potency) of PG synthetase in MVD associated with antinociceptive and potency
2) Confidence 0.66 Published 1991 Journal J. Med. Chem. Section Abstract Doc Link 1900533 Disease Relevance 0 Pain Relevance 0.68
Several groups have obtained evidence that resveratrol treatment increases the expression of the plasminogen activators t-PA and u-PA, suggesting that resveratrol could lead to plasminogen endoproteolysis and plasmin activation (Figure 1) [47,48].
Protein_catabolism (endoproteolysis) of plasmin
3) Confidence 0.58 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604890 Disease Relevance 0.13 Pain Relevance 0
In particular, Stachybotrys microspora triprenyl phenol-7 (SMTP-7; Orniplabin, MW 869.1, Fig. 1) is five to ten times more potent than staplabin in enhancing plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation (Hu et al. 2000).
Protein_catabolism (degradation) of plasminogen-mediated
4) Confidence 0.29 Published 2010 Journal Naunyn Schmiedebergs Arch Pharmacol Section Body Doc Link PMC2926440 Disease Relevance 0.68 Pain Relevance 0.03
In addition to Lp(a), serum plasminogen, alpha 2 antiplasmin, fibrinogen, and D-dimer (cross-linked fibrin degradation products) levels were measured.
Protein_catabolism (degradation) of plasminogen
5) Confidence 0.03 Published 1991 Journal Am. J. Cardiol. Section Abstract Doc Link 1827942 Disease Relevance 1.38 Pain Relevance 0.64
peptide, NEP [14], IDE [15], plasmin [33], and endothelin converting enzyme (ECE-1) [34] originate from a variety of cell types, degrade A?
Protein_catabolism (degrade) of plasmin
6) Confidence 0.01 Published 2009 Journal Mol Neurodegener Section Body Doc Link PMC2726140 Disease Relevance 0.68 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox